Previous 10 | Next 10 |
Total revenue of $18.3 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of mod...
Sportsman's Warehouse Holdings Inc. (SPWH) is expected to report $-0.3 for Q4 2024 IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2024-01-31 Klepierre (KLPEF) is expected to report for Q4 2023 Steakholder Foods Ltd. (STKH) is expected to report for Q4 2023 R...
2024-04-02 17:35:30 ET More on Simulations Plus Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI Simulations Plus, Inc. (SLP) Q1 2024 Earnings Call Transcript Simulations Plus, Inc. 2024 Q1 - Results - Earnings Call Presentation ...
Conference call to be on Wednesday, April 3, 2024, at 5 p.m. EDT Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024. Management...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc ...
2024-03-09 04:50:41 ET Summary Health Catalyst reported strong Q4 results, meeting guidance and showing growth in technology and professional services revenue. The drop in HCAT's share price presents a buying opportunity, as the company's growth initiatives, such as its TEMS offer...
Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use Simulations Plus, Inc . (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling a...
Strategic investments in early-stage companies to drive innovation and collaboration Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additi...
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February. The Company will be presenting at Oppenheimer’s 34 th ...
2024-02-01 15:27:39 ET Summary Today, we circle back on Simulations Plus, Inc., a health information services company focused on drug discovery and development software. Analysts have reissued Buy ratings on the stock, but the high valuation and potential competition from generati...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...